We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.
TODAY'S HIGH
3163
TODAY'S LOW
3092.8
52 WEEK HIGH
3786
52 WEEK LOW
2828
% of Shares Held by
All Insider
74.41%
% of Shares Held by
Institutions
18.39%
% of Float Held by
Institutions
71.89%
Number of Institutions
Holding Shares
83
MARKET CAP
37521.88 Cr.
ETERPRISE VALUE
36253.47 Cr.
NO. OF SHARES
11.95 Cr.
BOOK VALUE
764.572
DIV. YIELD
4%
DEBT
1927.20 Cr.
GROSS PROFIT
6353.55 Cr.
CASH
2755.11 Cr.
REVENUE
10758.58 Cr.
REVENUE/SHARE
899.872
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | -1205.11 Cr. | -928.62 Cr. | -445.39 Cr. | 166.22 Cr. |
| Change To Liabilities | 334.49 Cr. | 212.42 Cr. | -3.74 Cr. | -10.95 Cr. |
| Total cashflows from Investing Activities | -1435.13 Cr. | -998.54 Cr. | -741.35 Cr. | -316.39 Cr. |
| Net Borrowings | 841.61 Cr. | 116.65 Cr. | 583.77 Cr. | -105.73 Cr. |
| Total Cash from Financing Activities | 379.57 Cr. | -271.75 Cr. | 79.15 Cr. | -378.94 Cr. |
| Other Liabilities | 15.44 Cr. | -30.12 Cr. | -104.28 Cr. | 63.83 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 1645.62 Cr. | 1585.02 Cr. | 1127.07 Cr. | 760.51 Cr. |
| Change in Cash | 57.96 Cr. | -1.72 Cr. | -73.11 Cr. | 82.34 Cr. |
| Effect of Exchange Rate | 2.50 Cr. | 3.67 Cr. | 4.01 Cr. | -1.98 Cr. |
| Total Cash from Operating Activities | 1111.02 Cr. | 1264.90 Cr. | 585.08 Cr. | 779.65 Cr. |
| Depreciation | 303.96 Cr. | 264.82 Cr. | 243.61 Cr. | 185.17 Cr. |
| Other Cashflows from Investing Activities | 97.96 Cr. | 79.43 Cr. | 51.68 Cr. | 44.32 Cr. |
| Dividends Paid | -421.91 Cr. | -334.78 Cr. | -358.68 Cr. | -179.34 Cr. |
| Change to Inventory | -673.14 Cr. | -497.70 Cr. | -281.74 Cr. | -37.30 Cr. |
| Change to Account Receivables | -221.75 Cr. | -25.76 Cr. | -257.44 Cr. | -155.85 Cr. |
| Other Cashflows from Financing Activities | -40.13 Cr. | -53.62 Cr. | -145.94 Cr. | -93.87 Cr. |
| Change to Net Income | -293.60 Cr. | -253.54 Cr. | -147.55 Cr. | -33.77 Cr. |
| Capital Expenditures | -338.88 Cr. | -194.91 Cr. | -363.09 Cr. | -529.16 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 1844.28 Cr. | 1842.10 Cr. | 1259.79 Cr. | 954.66 Cr. |
| Minority Interest | 209.43 Cr. | 181.28 Cr. | 148.30 Cr. | 132.61 Cr. |
| Net Income | 1748.96 Cr. | 1674.77 Cr. | 1266.02 Cr. | 941.70 Cr. |
| Selling General Administrative | 1962.71 Cr. | 1980.72 Cr. | 2085.26 Cr. | 1872.82 Cr. |
| Gross Profit | 6453.90 Cr. | 5289.90 Cr. | 4921.07 Cr. | 4339.43 Cr. |
| Ebit | 1748.96 Cr. | 1674.77 Cr. | 1266.02 Cr. | 941.70 Cr. |
| Operating Income | 1748.96 Cr. | 1674.77 Cr. | 1266.02 Cr. | 941.70 Cr. |
| Other Operating Expenses | 2438.27 Cr. | 1360.81 Cr. | 1318.02 Cr. | 1333.01 Cr. |
| Interest Expense | -52.37 Cr. | -39.87 Cr. | -46.61 Cr. | -42.77 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 163.96 Cr. | 224.33 Cr. | 110.48 Cr. | 181.02 Cr. |
| Total Revenue | 10634.19 Cr. | 8865.01 Cr. | 8344.36 Cr. | 7357.19 Cr. |
| Total Operating Expenses | 8885.23 Cr. | 7190.24 Cr. | 7078.34 Cr. | 6415.49 Cr. |
| Cost of Revenue | 4180.29 Cr. | 3575.11 Cr. | 3423.29 Cr. | 3017.76 Cr. |
| Total Other Income Expense Net | 95.32 Cr. | 167.33 Cr. | -6.23 Cr. | 12.96 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 1680.32 Cr. | 1617.77 Cr. | 1149.31 Cr. | 773.64 Cr. |
| Net Income Applicable to Common Shares | 1645.62 Cr. | 1585.02 Cr. | 1127.07 Cr. | 760.51 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 211.54 Cr. | 84.44 Cr. | 98.39 Cr. | 44.26 Cr. |
| Capital Surplus | 0 | 0 | 0 | 0 |
| Total Liabilities | 5221.86 Cr. | 3961.25 Cr. | 3634.36 Cr. | 2636.24 Cr. |
| Stock Holder Equity | 8637.90 Cr. | 7376.73 Cr. | 6160.67 Cr. | 5439.34 Cr. |
| Minority Interest | 209.43 Cr. | 181.28 Cr. | 148.30 Cr. | 132.61 Cr. |
| Other Liabilities | 1039.62 Cr. | 195.99 Cr. | 202.11 Cr. | 138.21 Cr. |
| Total Assets | 14069.19 Cr. | 11519.26 Cr. | 9943.33 Cr. | 8208.19 Cr. |
| Common Stock | 23.91 Cr. | 23.91 Cr. | 23.91 Cr. | 23.91 Cr. |
| Retained Earnings | 0 | 7354 Cr. | 6103.74 Cr. | 5409.47 Cr. |
| Other Liabilities | 340.67 Cr. | 259.56 Cr. | 231.81 Cr. | 187.41 Cr. |
| Good Will | 403.09 Cr. | 395.39 Cr. | 398.45 Cr. | 380.56 Cr. |
| Treasury Stock | 8613.99 Cr. | -1.18 Cr. | 33.02 Cr. | 5.96 Cr. |
| Other Assets | 2160.88 Cr. | 1245.60 Cr. | 1064.38 Cr. | 860.89 Cr. |
| Cash | 2578.58 Cr. | 174.22 Cr. | 175.94 Cr. | 249.05 Cr. |
| Current Liabilities | 4805.34 Cr. | 3604.05 Cr. | 3243.31 Cr. | 2217.53 Cr. |
| Long Term Asset Charges | 1309.26 Cr. | 1107.91 Cr. | 932.57 Cr. | 707.63 Cr. |
| Short Long Term Debt | 2570.74 Cr. | 36.83 Cr. | 38.10 Cr. | 41.50 Cr. |
| Other Stockholder Equity | 8613.99 Cr. | -1.18 Cr. | 33.02 Cr. | 5.96 Cr. |
| Property Plant Equipment | 2626.58 Cr. | 2706.43 Cr. | 2774.14 Cr. | 2598.58 Cr. |
| Total Cur. Assets | 8435.43 Cr. | 6928.82 Cr. | 5496.03 Cr. | 4216.13 Cr. |
| Long Term Investments | 231.67 Cr. | 158.58 Cr. | 111.94 Cr. | 107.77 Cr. |
| Net Tangible Assets | 8023.27 Cr. | 6896.90 Cr. | 5663.83 Cr. | 5014.52 Cr. |
| Short Term Investments | 139.31 Cr. | 1412.34 Cr. | 116.27 Cr. | 178.10 Cr. |
| Net Receivables | 2078 Cr. | 1921.33 Cr. | 1910.95 Cr. | 1408.73 Cr. |
| Long Term Debt | 9.38 Cr. | 27.93 Cr. | 67.59 Cr. | 224.98 Cr. |
| Inventory | 3005.53 Cr. | 2312.44 Cr. | 1818.82 Cr. | 1499.87 Cr. |
| Accounts Payable | 1173.38 Cr. | 1069.41 Cr. | 954.05 Cr. | 962.25 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account